LordsMed, a healthcare division of Lord’s Mark Industries Ltd., has introduced a set of 10 high-quality re-agents for various tests, including Triglycerides, Uric Acid, Alkaline Phosphatase, Bilirubin, Calcium (Arsenazo III), Creatinine, Glucose, Serum Glutamic Oxaloacetic Transaminase (SGOT)/Aspartate Aminotransferas, Serum Glutamic Pyruvic Transaminase (SGPT), Alanine Aminotransferase (ALT) and Total Protein. The company has filed India patents for re-agents with 99.7% accuracy, highest sensitivity, 24-month shelf life, unique packaging, and competitive price-points, aiming to enhance preventive healthcare for critical diseases.
LordsMed plans to manufacture re-agents at its Maharashtra facility and distribute them to pathological labs, hospitals, and research institutes through its Pan-India distribution network of over 300 dealers. The company has plans to export the re-agent in key global markets. LordsMed aims to generate revenue by supplying these reagents Pan India and within SAARC, African and Eastern Europe countries in global markets within couple of years.
Lords Mark Industries is collaborating with IIT Bombay and Bhabha Atomic Research Centre to create world-class patent products for critical diseases like sickle cell, oral cancer, and tuberculosis. The aim is to develop affordable, high-accuracy re-agents. Commenting on the launch, Sachidanand Upadhyay, MD, Lord’s Mark Industries Ltd. said, “With our robust manufacturing capacity and domestic and global distribution network, we are working towards meeting the growing demand for quality re-agents across regions.”